- Home
- GRPN vs AUPH Comparison
GRPN vs AUPH Comparison
Compare GRPN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRPN
- AUPH
- Stock Information
- Founded
- GRPN 2008
- AUPH 1993
- Country
- GRPN United States
- AUPH Canada
- Employees
- GRPN N/A
- AUPH N/A
- Industry
- GRPN Advertising
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- GRPN Consumer Discretionary
- AUPH Health Care
- Exchange
- GRPN Nasdaq
- AUPH Nasdaq
- Market Cap
- GRPN 1.2B
- AUPH 1.4B
- IPO Year
- GRPN 2011
- AUPH 1999
- Fundamental
- Price
- GRPN $26.69
- AUPH $12.27
- Analyst Decision
- GRPN Buy
- AUPH Strong Buy
- Analyst Count
- GRPN 4
- AUPH 4
- Target Price
- GRPN $31.25
- AUPH $12.25
- AVG Volume (30 Days)
- GRPN 1.7M
- AUPH 2.8M
- Earning Date
- GRPN 08-06-2025
- AUPH 07-31-2025
- Dividend Yield
- GRPN N/A
- AUPH N/A
- EPS Growth
- GRPN N/A
- AUPH N/A
- EPS
- GRPN N/A
- AUPH 0.42
- Revenue
- GRPN $487,747,000.00
- AUPH $260,111,000.00
- Revenue This Year
- GRPN $3.48
- AUPH $12.15
- Revenue Next Year
- GRPN $8.16
- AUPH $18.34
- P/E Ratio
- GRPN N/A
- AUPH $29.18
- Revenue Growth
- GRPN N/A
- AUPH 25.59
- 52 Week Low
- GRPN $7.75
- AUPH $6.42
- 52 Week High
- GRPN $43.08
- AUPH $12.53
- Technical
- Relative Strength Index (RSI)
- GRPN 36.21
- AUPH 75.72
- Support Level
- GRPN $26.25
- AUPH $11.74
- Resistance Level
- GRPN $29.52
- AUPH $12.53
- Average True Range (ATR)
- GRPN 2.21
- AUPH 0.44
- MACD
- GRPN -0.44
- AUPH -0.00
- Stochastic Oscillator
- GRPN 2.61
- AUPH 80.74
About GRPN Groupon Inc.
Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.